Bank of Montreal Can Reduces Stock Position in Enovis Co. (NYSE:ENOV) (2025)

Table of Contents

Wall Street Analysts Forecast Growth Enovis Price Performance Enovis Profile See Also You might be interested in: References

Posted by Defense World Staff on Apr 24th, 2025

Bank of Montreal Can lessened its position in shares of Enovis Co. (NYSE:ENOV – Free Report) by 83.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,615 shares of the company’s stock after selling 32,543 shares during the quarter. Bank of Montreal Can’s holdings in Enovis were worth $290,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Quadrant Capital Group LLC raised its stake in shares of Enovis by 53.0% during the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock worth $30,000 after buying an additional 239 shares in the last quarter. Amalgamated Bank raised its position in shares of Enovis by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock worth $1,136,000 after purchasing an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the last quarter. Arizona State Retirement System grew its holdings in Enovis by 2.6% in the fourth quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock valued at $711,000 after purchasing an additional 414 shares during the period. Finally, UMB Bank n.a. raised its holdings in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of Enovis in a research report on Wednesday, April 9th.

View Our Latest Report on ENOV

Enovis Price Performance

Shares of NYSE:ENOV opened at $33.82 on Thursday. The stock has a fifty day moving average of $36.88 and a 200-day moving average of $42.01. The company has a market capitalization of $1.93 billion, a PE ratio of -15.44 and a beta of 1.86. Enovis Co. has a one year low of $29.32 and a one year high of $56.43. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $560.98 million during the quarter, compared to analyst estimates of $555.14 million. As a group, equities analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

(Free Report)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

You might be interested in:

Bank of Montreal Can Sells 106,236 Shares of Under Armour, Inc.

Bank of Montreal Can Has $291,000 Position in Tidewater Inc.

Bank of Montreal Can Purchases 131 Shares of UniFirst Co.

Bank of Montreal Can Has $317,000 Stock Position in Inari Medical, Inc.

Bank of Montreal Can Has $304,000 Stock Holdings in Insperity, Inc.

Bank of Montreal Can Increases Stock Holdings in The Boston Beer Company, Inc.